SCHEMBL2290948

SCHEMBL2290948

CNCC(=O)Nc1ccc(-c2nc3ccccn3c2Nc2c(C)cccc2C)c(OCC(N)=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.44
GAA P10253 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 5/20 0.42
RXFP1 Q9HBX9 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2287301 0.89 MAPT (0.44) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2290726 0.89 TRPA1 (0.39) MAPTGAANPSR1TP53RXFP1
SCHEMBL2290950 0.88 MAPT (0.44) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2290860 0.86 GAA (0.51) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2289741 0.86 GAA (0.51) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2289779 0.86 GAA (0.44) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2294380 0.84 GAA (0.49) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2288909 0.84 GAA (0.49) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2294105 0.84 TP53 (0.49) MAPTGAASMN1; SMN2NPSR1MAPK1
SCHEMBL2288504 0.84 GAA (0.54) MAPTGAASMN1; SMN2NPSR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 MAPT 1138/4885GAA 1202/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.